MAP3K

MAP3K Related Products (28):

By Effects:	Inhibitors (23) Activator (1) Degrader (1)

Cat. No.	Product Name	Effect	Purity

HY-112136

TAO Kinase inhibitor 1	Inhibitor	99.46%
TAO Kinase inhibitor 1 (compound 43) is a selective, ATP-competitive thousand-and-one amino acid kinases (TAOK) inhibitor with IC₅₀s of 11 to 15 nM for TAOK1 and 2, respectively. TAO Kinase inhibitor 1 delays mitosis and induces mitotic cell death.

HY-12947

GNE-3511	Inhibitor	99.54%
GNE-3511 is an orally active bioavailable and brain-penetrant dual leucine zipper kinase (DLK) inhibitor with a K_i of 0.5 nM. GNE-3511 can cross the blood-brain-barrier and can be used for the research of neurodegenerative diseases.

HY-32018

Cot inhibitor-2	Inhibitor	99.65%
Cot inhibitor-2 is a potent, selective and orally active cot (Tpl2/MAP3K8) inhibitor with an IC₅₀ of 1.6 nM. Cot inhibitor-2 inhibts TNF-α production in LPS-stimulated human whole blood with an IC₅₀ of 0.3 μM.

HY-124953

7,3',4'-Trihydroxyisoflavone	Inhibitor	99.83%
7,3',4'-Trihydroxyisoflavone, a major metabolite of Daidzein, is an ATP-competitive inhibitor of Cot (Tpl2/MAP3K8) and MKK4. 7,3',4'-Trihydroxyisoflavone has anticancer, anti-angiogenic, chemoprotective, and free radical scavenging activities.

HY-114332

GNE-8505	Inhibitor	99.86%
GNE-8505 is an orally available inhibitor of Dual leucine zipper kinase (DLK).

HY-136807

Tpl2-IN-I	Inhibitor
Tpl2-IN-I functions as an inhibitor of the Tpl2 (tumour progression locus 2) kinase.

HY-170595

PROTAC LZK-IN-1	Degrader
PROTAC LZK-IN-1 (Compound 21A) is a PROTAC that targets the degradation of LZK (Leucine Zipper Kinase, encoded by MAP3K13). PROTAC LZK-IN-1 (10 μM) promotes the degradation of LZK and inhibits the expression of p53 and c-MYC, leading to reduced viability of global head and neck squamous cell carcinoma (HNSCC) cell lines. PROTAC LZK-IN-1 can be used in cancer research. PROTAC LZK-IN-1 consists of an E3 ligase ligand (blue part, HY-112078), a target protein ligand (red part, HY-170596), and a linker (black part, HY-W019543)[1].

HY-169949

TAK-756	Inhibitor
TAK-756 is a TAK1 inhibitor with good selectivity for IRAK1/4 and excellent intra-articular pharmacokinetic properties. TAK1 is a potential molecular target for osteoarthritis (OA) with complementary anti-catabolic and anti-inflammatory effects.

HY-32015

Cot inhibitor-1	Inhibitor	98.45%
Cot inhibitor-1 (compound 28) is a selective tumor progression loci-2 (Tpl2) kinase inhibitor with an IC₅₀ of 28 nM. Cot inhibitor-1 shows an inhibition of TNF-alpha production in human whole blood with an IC₅₀ of 5.7 nM.

HY-114331

DLK-IN-1	Inhibitor	99.18%
DLK-IN-1 is a selective, orally active inhibitor of dual leucine zipper kinase (DLK, MAP3K12), with a K_i of 3 nM. DLK-IN-1 retains excellent CNS penetration and is well tolerated following multiple days of dosing at concentrations that exceed those required for DLK inhibition in the brain. DLK-IN-1 has activity in a model of Alzheimer’s Disease.

HY-119608

GSK854	Inhibitor	98.40%
GSK854 is a potent Inhibitor of Troponin I-Interacting Kinase (TNNI3K). GSK854 is a suitable lead for identifying new cardiac medicines and have been employed as in vivo tools in investigational studies aimed at defining the role of TNNI3K within heart failure.

HY-117243

GSK329	Inhibitor	99.60%
GSK329 is a potent and selective diarylurea inhibitor of the cardiac-specific kinase TNNI3K. GSK329 exhibits positive cardioprotective outcomes in the model of ischemia/reperfusion cardiac injury.

HY-136849

TL13-68	Inhibitor	98.88%
TL13-68 is a biotin-tagged version of SM1-71, and it can be used to research the mechanism of SM1-71.

HY-117658

GSK-114	Inhibitor	98.08%
GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC₅₀= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC₅₀= 1 μM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue.

HY-15434A

NG25 trihydrochloride	Inhibitor
NG25 trihydrochloride is a dual TAK1 and MAP4K2 inhibitor (IC₅₀: 149 nM and 21.7 nM respectively). NG25 sensitizes the breast cancer cells to Doxorubicin (HY-15142A), and enhances apoptosis. NG25 trihydrochloride can be used for research of various cancers.

HY-124059

SW-034538	Inhibitor
SW-034538 is a TAO2 inhibitor, with an IC₅₀ of 300 nM.

HY-153320

AZ-TAK1	Inhibitor
AZ-TAK1, an ATP-competitive small molecule inhibitor of TAK1, dephosphorylates TAK1, p38, and IκB-α in lymphoma cell lines.

HY-124152

3,4-Dephostatin	Inhibitor
3,4-Dephostatin (Methyl-3,4-dephostatin) is an inhibitor of protein-tyrosine phosphatase (PTPase). 3,4-Dephostatin accelerates nerve growth factor (NGF)-induced neurite formation in PC12h cells. 3,4-Dephostatin sustains the NGF-induced tyrosine phosphorylation of proteins, most prominently that of mitogen-activated protein (MAP) kinase. 3,4-Dephostatin also prolongs epidermal growth factor (EGF)-induced tyrosine phosphorylation and activation of MAP kinase.

HY-122232

SW083688	Inhibitor
SW083688 is a potent, highly selective TAOK2 (Thousand-And-One Kinase 2) inhibitor (IC₅₀ values = 1.3 umol/L).

HY-155089

IACS-52825	Inhibitor
IACS-52825 is a potent and selective DLK inhibitor with K_d of 1.3 nM, useful for the study of chemotherapy-induced peripheral neuropathy.

Name
Email *

	Sorry, but the email address you supplied was invalid.